Keyphrases
DANBIO Registry
81%
Rheumatoid Arthritis
71%
Biosimilar
70%
Routine Care
54%
Inflammatory Arthritis
50%
Clinical Outcomes
50%
Biologic DMARDs
47%
Adalimumab
47%
Rheumatoid Arthritis Patients
46%
Psoriatic Arthritis
42%
Clinical Remission
37%
Inflammatory Rheumatic Diseases
34%
Real Patients
34%
Infliximab
34%
Treat-to-target
31%
Methotrexate
31%
Drug Survival
31%
Retention Rate
29%
Infliximab Biosimilar
28%
Axial Spondyloarthritis (AxSpA)
26%
Disease Activity
26%
Ultrasound
25%
CT-P13
25%
Remission
24%
Switcher
23%
Treatment Response
23%
Radiographic Progression
20%
Early Rheumatoid Arthritis
19%
Treatment Drugs
19%
Non-medical Switching
18%
Intra-articular
18%
Clinical Response
18%
Disease Activity Score
17%
Disease Activity Score 28 (DAS28)
16%
Dose Tapering
15%
Doppler Ultrasound
15%
Danish National Patient Registry
15%
Treatment Optimization
15%
Treatment Algorithm
15%
Patient Register
15%
Biological Disease-modifying Antirheumatic Drugs (bDMARDs)
15%
Rheumatoid Arthritis Diagnosis
15%
Hand Bone Loss
15%
Randomized Clinical Trial
15%
Randomized Controlled Trial
15%
Investigator-initiated
15%
Radiographic Outcomes
15%
Nationwide Registry
15%
Comparative Effectiveness
15%
Nationwide Observational Study
15%
Medicine and Dentistry
Rheumatoid Arthritis
100%
Biosimilar
62%
Infliximab
47%
Adalimumab
47%
Psoriatic Arthritis
44%
Disease Activity
37%
Rheumatic Disease
35%
Methotrexate
31%
Spondylarthritis
29%
Treatment Response
23%
TNF Inhibitor
18%
Observational Study
17%
Etanercept
15%
Patient Registry
15%
Osteolysis
15%
Drug Response
15%
Magnetic Resonance Imaging
15%
Hand Bone
15%
Patient-Reported Outcome
15%
Randomized Clinical Trial
15%
Drug Dose Regimen
15%
Randomized Controlled Trial
15%
Glucocorticoid
15%
Ankylosing Spondylitis
15%
Cohort Study
13%
Disease Modifying Antirheumatic Drug
11%
Rheumatology
11%
Proportional Hazards Model
10%
DAS28
9%
Treatment Duration
7%
BASDAI
7%
Spontaneous Remission
7%
Triamcinolone
7%
Adverse Event
7%
Health Assessment Questionnaire
6%
Bone Density
6%
Body Weight
6%
Ankylosing Spondylitis Disease Activity Score
5%
Disease Duration
5%
Visual Analog Scale
5%
Drug Effect
5%
